Olema Pharmaceuticals Inc. OLMA
$9.52
▲ +1.23% 24H
About
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral therapy that acts as both a complete estrogen recept…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees137
TickerOLMA
Statistics
Market Cap$831.4M
Revenue (TTM)$0
Net Income-$162.5M
Net Margin—
EPS$-1.87
P/E-5.28
P/S—
P/B1.66
EV/EBITDA-1.83
ROE-42.9%
Dividend Yield—
Price$9.52
Data: Twelve Data · Revenue = mcap / P/S